Placebo and nocebo effects in pain

Placebo analgesia is real neurobiology, partly mediated by endogenous opioids and prefrontal top-down control, and nocebo effects arise from negative expectation and conditioning; how clinicians frame information changes pain and side effects.

1. Naloxone unmasked the opioid component. After third molar extraction under local block, in a randomized double-blind study, naloxone raised pain only in placebo responders, and that increase fully explained the responder–nonresponder difference, supporting endorphin-mediated placebo analgesia ¹.
2. Not all placebo analgesia is opioid. Imaging re-analysis found lateral orbitofrontal and ventrolateral prefrontal activation greater with placebo than opioid analgesia, supporting prefrontal top-down influence on the rostral anterior cingulate ².
3. Expectation error may matter. Petrovic and colleagues propose that placebo meets expectations less fully than active drug, producing a larger error signal that drives the prefrontal response ².
4. Deception is not essential. In a 3-week randomized trial of 80 IBS patients, open-label placebo pills given honestly improved global symptoms more than no-treatment care with matched provider interaction, already at the 11-day midpoint ³.
5. Nocebo is the negative mirror. A nocebo effect is a negative symptom induced by sham treatment or negative expectations; nocebo responses can follow negative suggestion by staff even without treatment ⁴.
6. Mechanisms are learning and expectation. Nocebo effects arise from Pavlovian conditioning and expectations created by verbal information or suggestion ⁴.

Information about possible complications, and negative expectations, increase the likelihood of adverse effects; Häuser suggests emphasizing that treatment is usually well tolerated, or obtaining permission to give less detailed side-effect information ⁴.

• The opioid-rich rostral anterior cingulate is active in both placebo and opioid analgesia; opioids act directly on descending inhibition, whereas placebo depends on neocortical top-down control ².
• In the dental study, nonresponders' final pain matched that of responders given naloxone ¹.
• The open-label placebo trial used Rome III-diagnosed IBS with symptom severity of at least 150 ³.
• Some adverse events during drug treatment arise from nocebo effects, and information about possible complications raises their likelihood ⁴.
• Häuser frames an ethical dilemma: clinicians must inform patients of complications yet avoid inducing them through nocebo ⁴.
• Communication training is recommended so clinicians use words to patients' benefit ⁴.
• Trial NNTs subtract the placebo response: NNT is the reciprocal of the absolute difference between active and control event rates ⁵.

• Treating a placebo response as evidence that pain was not real; it has an endogenous opioid mechanism ¹.
• Assuming all placebo analgesia is naloxone-reversible ².
• Believing placebo requires deception to work ³.
• Listing every possible side effect in alarming terms without noting that most patients tolerate treatment well ⁴.